Leuven, BELGIUM, Boston, MA, US – September 7, 2022 – 8.00 am CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical firm creating subsequent technology normal of care ophthalmic therapies, with medical stage belongings in vascular retinal issues, at present revealed its monetary and business replace for the six-month interval ending June 30, 2022.
The half-year report is accessible within the “Investors” part of the Company’s web site and may also be downloaded as a PDF.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical firm creating subsequent technology normal of care ophthalmic therapies, that are designed to enhance and higher protect imaginative and prescient in sufferers with retinal issues together with diabetic macular edema (DME), the main explanation for imaginative and prescient loss in working-age individuals, in addition to different situations. Oxurion intends to play an necessary function within the therapy of retinal issues, together with the profitable improvement of THR-149, its novel therapeutic for the therapy of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a possible new normal of look after the as much as 50% of DME sufferers displaying suboptimal response to anti-VEGF remedy. Oxurion is headquartered in Leuven, Belgium, with company operations in Boston, MA. More data is accessible at www.oxurion.com.
For additional data please contact:
| Oxurion NV Tom Graney Chief Executive Officer Tel: +32 16 75 13 10 [email protected]
Michael Dillen
|
US Conway Communications Beth Kurth [email protected]
ICR Westwicke |
- OXUR 1H 2022 2022.0907 FINAL
